Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Unite Group enters into JV framework agreement with Manchester Metropolitan University

(Sharecast News) - Student accommodation business Unite has entered into a joint venture framework agreement with Manchester Metropolitan University for the development of 2,300 new student beds at the University's Cambridge Halls site in Manchester city centre for delivery in 2029 and 2030. Unite said on Thursday that Manchester Metropolitan University has committed to closing the existing accommodation on the site, with work due to commence on-site later in 2025 and construction expected to commence in 2026.

The FTSE 100-listed group said total development costs for the project will be roughly £390.0m, with Manchester Metropolitan University owning a 30% stake in the JV, reflecting the contribution of the Cambridge Halls site.

Unite's equity commitment was expected to be around £125.0m for a 70% stake, which will be funded from internally generated sources, with the remaining funding coming from debt secured against the JV.

The project was expected to deliver returns comparable with developments in regional cities, which also reflects the fees Unite will receive as development and asset manager to the JV. To support the University's accommodation requirements during the development phase, the company has separately entered into a five-year nomination agreement for 2,550 beds in other Unite Students' properties in Manchester. Submission of the planning application for the development was expected later in Q2, which would support the formation of the JV around the end of 2025.

As of 0815 BST, Unite shares were up 0.12% at 861.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.